Skip to main content
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC — Investor Relations & Filings

Ticker · BCYC ISIN · US0887861088 LEI · 213800XKUI6R7GKC3E43 US Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2019-05-30 Director's Dealing
Country GB United Kingdom
Listing US BCYC

About BICYCLE THERAPEUTICS PLC

https://www.bicycletherapeutics.com/

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic bicyclic peptides engineered to combine the targeting specificity and pharmacological properties of large molecule biologics with the rapid and deep tissue penetration of small molecules. The company's proprietary platform creates precision-guided therapeutics to address diseases underserved by existing treatments. The primary focus of its development pipeline is in oncology, with a portfolio of candidates designed to target solid tumors. Beyond oncology, Bicycle Therapeutics leverages its technology through collaborations to explore applications in other therapeutic areas, including anti-infectives, cardiovascular diseases, and central nervous system disorders.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2019-05-30 English
Regulatory Filings 2019
Regulatory Filings
2019-05-24 English
Regulatory Filings 2019
Regulatory Filings
2019-05-24 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as share option plans and employee share purchase plans. It includes detailed information about the securities to be registered, the plans under which they are offered, and legal and indemnification provisions related to directors and officers. This type of filing is a regulatory registration statement related to capital raising through employee stock plans, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration statement itself. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-05-23 English
424B4
Capital/Financing Update Classification · 95% confidence The document is a 424B4 prospectus filed pursuant to Rule 424(b)(4) related to an initial public offering (IPO) of American Depositary Shares (ADSs) of Bicycle Therapeutics plc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, capitalization, management, and financial data. The document is a registration/prospectus filing for a capital raising event, specifically an IPO. This type of document is best classified as a Capital/Financing Update (CAP) because it provides updates on the company's fundraising and capital structure changes. It is not an annual or interim report, earnings release, or other types of filings. The document length is substantial (15,000 characters), and it contains detailed offering information, underwriting details, and financial data relevant to the capital raise.
2019-05-23 English
FORM 3
Director's Dealing
2019-05-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.